Biotech Late Stage Investors & VC Firms
652 firms in this list, with a median first check of $1M. 131 of them lead rounds. Generated from verified public data and updated continuously.
Sangel Capital
ShenzhenSeed–Late Stage
Hotung Investment Holdings Ltd.
SingaporeSeries A–Late Stage$300K – $1.5M
VentureTECH
SelangorSeries A–Late Stage$1.6M – $10M
Teuza
HaifaPre-Seed–Late Stage$250K – $2M
5 people
Sustainable Conversion Ventures
Sun LakesSeed–Late Stage
2 people
Aescuvest
Frankfurt am MainSeed–Late Stage
1 person
Gilmartin Capital LLC
LarkspurSeries A–Late Stage
2 people
Darwin Venture Management
TaipeiSeed–Late Stage$1M – $76M
Elmirate Capital
DubaiSeed–Late Stage$1M – $250M
Hony Capital Ltd.
Hong KongGrowth–Late Stage$6M
6 people
Innovation Engine
TokyoPre-Seed–Late Stage
3 people
IRDI SORIDEC Gestion
ToulouseSeed–Late Stage$216K – $16.2M
JAFCO Group
TokyoPre-Seed–Late Stage$1.9M – $198M
BioRock Ventures
San FranciscoPre-Seed–Late Stage
1 person
Kohli Ventures
Grand CaymanSeed–Late Stage
1 person
Northwell Holdings
New YorkSeed–Late Stage
1 person
Mayo Clinic Ventures
RochesterSeed–Late Stage
2 people
MB Venture Partners
MemphisPre-Seed–Late Stage
2 people
Mirae Asset Venture Investment
Seed–Late Stage$594K – $54M
2 people
Reverent Partners
SeoulSeries A–Late Stage
Schouten Investments
AmsterdamSeries B–Late Stage
2 people
venture / science
San Francisco Bay AreaSeed–Late Stage
2 people
Lundbeckfonden Ventures
CopenhagenPre-Seed–Late Stage
1 person
Mitsui Sumitomo Insurance Capital
TokyoPre-Seed–Late Stage$1.1M – $198M
1 person
Related lists
Late Stage Investors & VC Firms (2974)Biotech Investors & VC Firms (2185)Biotech Seed Investors & VC Firms (1824)Late Stage Investors & VC Firms in North America (1695)Biotech Series A Investors & VC Firms (1668)Late Stage Investors & VC Firms in United States (1516)Biotech Investors & VC Firms in North America (1391)Biotech Investors & VC Firms in United States (1267)Late Stage Investors & VC Firms in Europe (965)Biotech Pre-Seed Investors & VC Firms (957)
Data sourced from public filings and firms' own websites — see our methodology.
















